Enzymatic and cellular study of a serotonin N-acetyltransferase phosphopantetheine-based prodrug.

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Bioorganic & Medicinal Chemistry (Impact Factor: 2.95). 04/2007; 15(5):2147-55. DOI: 10.1016/j.bmc.2006.12.016
Source: PubMed

ABSTRACT Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) regulates the daily rhythm in the production of melatonin and is therefore an attractive target for pharmacologic modulation of the synthesis of this hormone. Previously prepared bisubstrate analogs show potent inhibition of AANAT but have unfavorable pharmacokinetic properties due to the presence of phosphate groups which prevents transfer across the plasma membrane. Here, we examine a bis-pivaloyloxymethylene (POM)-tryptamine-phosphopantetheine prodrug (2) and its biotransformations in vitro by homogenates and pineal cells. Compound 2 is an efficient porcine liver esterase substrate for POM cleavage in vitro although cyclization of the phosphate moiety is a potential side product. Tryptamine phosphopantetheine (3) is converted to tryptamine-coenzyme A (CoA) bisubstrate analog (1) by human phosphoribosyl pyrophosphate amidotransferase (PPAT) and dephosphocoenzyme A kinase (DPCK) in vitro. Compound 2 was found to inhibit melatonin production in rat pineal cell culture. It was also found that the POM groups are readily removed to generate 3; however, further processing to tryptamine-CoA (1) is much slower in pineal extracts or cell culture. Implications for CoA prodrug development based on the strategy used here are discussed.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Carrier proteins are central to the biosynthesis of primary and secondary metabolites in all organisms. Here we describe metabolic labeling and manipulation of native acyl carrier proteins in both type I and II fatty acid synthases. By utilizing natural promiscuity in the CoA biosynthetic pathway in combination with synthetic pantetheine analogues, we demonstrate metabolic labeling of endogenous carrier proteins with reporter tags in Gram-positive and Gram-negative bacteria and in a human carcinoma cell line. The highly specific nature of the post-translational modification that was utilized for tagging allows for simple visualization of labeled carrier proteins, either by direct fluorescence imaging or after chemical conjugation to a fluorescent reporter. In addition, we demonstrate the utility of this approach for the isolation and enrichment of carrier proteins by affinity purification. Finally, we use these techniques to identify a carrier protein from an unsequenced organism, a finding that validates this proteomic approach to natural product biosynthetic enzyme discovery.
    ChemBioChem 04/2009; 10(6):1091-100. · 3.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coenzyme A (CoA) analogues are widely used as tools in chemical biology. Currently, most CoA analogues are prepared by biotransformation of pantothenic acid analogues using the three CoA biosynthetic enzymes (PanK, PPAT, and DPCK) that constitute the CoA salvage pathway. However, because the enzymes are usually lost or destroyed in the solution-based methods that are presently used, we created fusions of the Escherichia coli and Staphylococcus aureus PanK, PPAT, and DPCK enzymes with a cellulose-binding domain (CBD) which can be used to immobilize each of these proteins on cellulose. We show that all the CBD-fusion proteins can be expressed in soluble form, and that instead of impacting negatively on the activity of their enzyme partners, the presence of the CBD improves their kinetic profiles in some cases. We subsequently determined which combinations of the available enzymes are most effective in producing CoA and a typical CoA analogue, and used these to demonstrate that the rate of biotransformation is not severely affected even when the CBD-fusion enzymes are immobilized on cellulose. Finally, we constructed batch and column reactors from cellulose loaded with the CBD enzymes and tested these in the biocatalytic production of a fluorescent CoA analogue often used for protein labeling. Our results show that such reactors can successfully be used, and that the enzymes retain their activities upon storage in this format. This study is the first to showcase the use of a multi-enzyme reactor system based on CBD-fusion proteins in biocatalysis.
    ChemCatChem 09/2010; 2(10):1239 - 1251. · 5.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coenzyme A (CoA) analogues are widely used as tools in chemical biology. Their applications include being used as inhibitors and mechanistic probes of CoA-dependent enzymes, and in the labeling of especially carrier proteins active in polyketide and nonribosomal peptide synthesis with fluorescent probes or affinity tags, or with chemically reactive cross-linking moieties. The preparation of CoA analogues has been simplified tremendously since the discovery of the CoA biosynthetic enzymes. Consequently a large number of such analogues have been prepared in recent years by the biotransformation of pantothenamide precursors (a bottom-up approach) or by aminolysis of activated pre-CoA thioesters (a top-down approach). This Minireview provides an analysis of the biosynthetic enzymes used in the biocatalytic production of CoA analogues, an overview of the different ways in which they are currently applied and a description of the types of CoA analogues that are currently easily accessed by such methods.
    ChemCatChem 08/2010; 2(8):929 - 937. · 5.18 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014